Airleaf™: A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis (Boehringer_1397- 0012)

The primary objective of the study is to demonstrate a non-flat dose response curve and evaluate the dose-response relationship for 3 oral dosing regimens of BI 1291583 versus placebo on the primary endpoint, the time to first pulmonary exacerbation up to week 48.